These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The Human and Economic Burden of Difficult-to-Treat Gouty Arthritis. Bardin T; Voshaar MA; van de Laar MA Joint Bone Spine; 2015 Oct; 82 Suppl 1():eS2-8. PubMed ID: 26717799 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics considerations for gout treatments. Richette P; Frazier A; Bardin T Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):949-57. PubMed ID: 24809930 [TBL] [Abstract][Full Text] [Related]
7. Longitudinal transition trajectory of gouty arthritis and its comorbidities: a population-based study. Huang CF; Liu JC; Huang HC; Chuang SY; Chen CI; Lin KC Rheumatol Int; 2017 Feb; 37(2):313-322. PubMed ID: 28004164 [TBL] [Abstract][Full Text] [Related]
8. Gouty arthritis: understanding the disease state and management options in primary care. Sunkureddi P Adv Ther; 2011 Sep; 28(9):748-60. PubMed ID: 21894471 [TBL] [Abstract][Full Text] [Related]
9. [Current opinions on gout, its diagnosis and treatment]. Němec P Vnitr Lek; 2012 Dec; 58(12):928-37. PubMed ID: 23427951 [TBL] [Abstract][Full Text] [Related]
10. [Pathogenesis, diagnostics and therapy of gout]. Zurek M Vnitr Lek; 2006; 52(7-8):736-41. PubMed ID: 16967617 [TBL] [Abstract][Full Text] [Related]
11. Does prolonged systemic glucocorticoid use increase risk of tophus formation among gouty arthritis patients? Raso AA; Sto Niño OV; Li-Yu J Int J Rheum Dis; 2009 Sep; 12(3):243-9. PubMed ID: 20374354 [TBL] [Abstract][Full Text] [Related]
12. Advances in the management of gout and hyperuricaemia. Hoskison TK; Wortmann RL Scand J Rheumatol; 2006; 35(4):251-60. PubMed ID: 16882587 [TBL] [Abstract][Full Text] [Related]
13. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review. Vinik O; Wechalekar MD; Falzon L; Buchbinder R; van der Heijde DM; Bombardier C J Rheumatol Suppl; 2014 Sep; 92():70-4. PubMed ID: 25180131 [TBL] [Abstract][Full Text] [Related]
14. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Saseen JJ; Agashivala N; Allen RR; Ghushchyan V; Yadao AM; Nair KV Rheumatology (Oxford); 2012 Nov; 51(11):2004-12. PubMed ID: 22829689 [TBL] [Abstract][Full Text] [Related]
15. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Perez-Ruiz F; Atxotegi J; Hernando I; Calabozo M; Nolla JM Arthritis Rheum; 2006 Oct; 55(5):786-90. PubMed ID: 17013833 [TBL] [Abstract][Full Text] [Related]
16. What makes gouty inflammation so variable? Terkeltaub R BMC Med; 2017 Aug; 15(1):158. PubMed ID: 28818081 [TBL] [Abstract][Full Text] [Related]
17. P2X7R: a potential key regulator of acute gouty arthritis. Tao JH; Zhang Y; Li XP Semin Arthritis Rheum; 2013 Dec; 43(3):376-80. PubMed ID: 23786870 [TBL] [Abstract][Full Text] [Related]
18. Treatment of hyperuricemia, gout and other crystalline arthritidies. Lioté F Reumatismo; 2012 Jan; 63(4):276-83. PubMed ID: 22303534 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature. Aouba A; Deshayes S; Frenzel L; Decottignies A; Pressiat C; Bienvenu B; Boue F; Damaj G; Hermine O; Georgin-Lavialle S Mediators Inflamm; 2015; 2015():792173. PubMed ID: 25922564 [TBL] [Abstract][Full Text] [Related]
20. Gouty arthritis in acute cerebrovascular disease. Lin YH; Hsu HL; Huang YC; Lee M; Huang WY; Huang YC; Lee TH; Lee JD Cerebrovasc Dis; 2009; 28(4):391-6. PubMed ID: 19696479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]